Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Subhash C. Gulati"'
Publikováno v:
European Journal of Haematology. 43:164-172
To assess the usefulness of 4-hydroperoxycyclophosphamide (4-HC) and Etoposide (VP-16) as a purging agent for myeloma cells in bone marrow ex-vivo, myeloma cell lines (SK-RCS-1, RPMI-8226), lymphoma cell line (SK-DHL-2) and normal bone marrow (BM) ce
Autor:
Subhash C. Gulati, M. Jhanwar-Uniyal
Publikováno v:
Leukemia & Lymphoma. 29:415-421
Mutations of the p53 tumor suppressor gene have been used as molecular genetic markers of disease and serve as a prognostic indicator in various malignancies including non-Hodgkin's lymphoma (NHL). Alterations in the p53 gene were investigated in a b
Publikováno v:
Molecular Medicine Reports.
Understanding of molecular regulatory pathways presents a novel therapeutic approach for the treatment of head and neck cancer. These specific check points are becoming the targeted therapeutic approach. In this review, we highlight certain major sig
Publikováno v:
Cancer letters. 323(2)
With growing epidemiologic and molecular evidence linking the pathogenesis of diabetes mellitus and oncogenesis, the role of anti-diabetic drugs as antineoplastic agents becomes a subject of intense investigation. Several trials are underway assessin
Publikováno v:
The Indian Journal of Pediatrics. 61:469-473
The future directions of high dose chemotherapy with stem cell support will focus ultimately on improving survival.5,19 This will come about with improvements in our ability to re-infuse pristine stem cells without tumor contaminants, and to recogniz
Publikováno v:
Cancer Investigation. 12:336-342
Randomized phase III clinical trials provide important information on the efficacy of new pharmaceutical agents for cancer patients. Policy makers are showing increased interest in both economic and clinical data on new agents in order to approve pha
Autor:
George J. Bosl, Vaia Vlamis, Dean F. Bajorin, Madhu Mazumdar, Subhash C. Gulati, Robert J. Motzer, P Lyn
Publikováno v:
JNCI Journal of the National Cancer Institute. 85:1828-1835
BACKGROUND Between 20% and 30% of patients with advanced germ cell tumors (GCTs) fail to have durable complete response to conventional cisplatin-based induction chemotherapy. However, third-line therapy with high-dose carboplatin and etoposide plus
Publikováno v:
Anti-Cancer Drugs. 4:13-16
Use of growth factors to augment hematopoietic recovery after cytotoxic therapy is a useful method for dose intensification. We wanted to evaluate the clinical and cost-effectiveness of granulocyte-macrophage colony stimulating factor (GM-CSF; Leucom
Autor:
Tzy-Jyun Yao, Malcolm A.S. Moore, Robert T. Heelan, John Crown, Subhash C. Gulati, Beryl McCormick, Robert J. Motzer, A Kritz, Michael P. Moore, J Schneider, Glenn Heller, Nicola Hamilton, Larry Norton, Teresa Gilewski, Richard J. O'Reilly, Lilian Reich
Publikováno v:
Cancer. 71:2515-2521
BACKGROUND This study compared the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) alone or in combination with peripheral blood-derived hematopoietic progenitor cells (PBP) as support for patients receiving high-dose chemothera
Autor:
Jens Atzpodien, Subhash C. Gulati
Publikováno v:
STEM CELLS. 11:511-518
The lymphokine-activated killer (LAK) phenomenon is generally referred to as nonspecific, i.e., major histocompatibility complex (MHC)-unrestricted cytotoxicity against tumor cells generated by ex vivo culture of human peripheral blood lymphocytes wi